Alprazolam Orally Disintegrating Tablets CIV
Generic Name and Formulations:
Alprazolam 0.25mg, 0.5mg. 1mg, 2mg; scored tabs; orange flavor.
Various generic manufacturers
Indications for Alprazolam Orally Disintegrating Tablets:
Anxiety disorder. Short-term treatment of anxiety symptoms. Panic disorder (with or without agoraphobia).
≥18yrs: Anxiety: Initially 0.25–0.5mg three times daily. May increase at 3–4 day intervals to 4mg/day in divided doses. Panic: Initially 0.5mg three times daily; may increase at intervals of 3–4 days in increments of up to 1mg/day; usual max 10mg/day. Advanced liver disease, elderly, or debilitated: initially 0.25mg 2–3 times daily. For all: individualize; reevaluate periodically; withdraw gradually.
<18yrs: not recommended.
Acute narrow-angle glaucoma. Concomitant itraconazole, ketoconazole.
Risks from concomitant use with opioids; see Interactions. Not for use in untreated open-angle glaucoma. Discard unused portions of scored tabs (drug stability not ensured). Suicidal ideation. Depression. Psychosis. Mania. Renal, cardiovascular, hepatic, or pulmonary impairment; monitor. Obesity. Reevaluate periodically. Change dose gradually. Withdrawal symptoms on abrupt cessation or dose reduction. Monitor periodic CBCs, urinalysis, blood chemistry. Drug or alcohol abuse. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.D), nursing mothers: not recommended.
See Contraindications; other azole antifungals: not recommended. Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants (eg, other benzodiazepines, psychotropics, anticonvulsants, antihistamines); consider dose reductions. Potentiated by CYP3A inhibitors (eg, cimetidine, nefazodone, fluvoxamine); reduce alprazolam dose; caution with weaker CYP3A inhibitors (eg, fluoxetine, propoxyphene, oral contraceptives). Caution with diltiazem, isoniazid, erythromycin, clarithromycin, grapefruit juice, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A. Antagonized by CYP3A inducers (eg, carbamazepine). May increase levels of imipramine, desipramine. Absorption may be affected by drugs or conditions that affect salivation or gastric pH.
CNS depression (eg, sedation, somnolence, memory impairment, dysarthria, coordination abnormal, ataxia), fatigue, lethargy, dyspnea, dry mouth, constipation, withdrawal seizures, tremors, decreased libido, sexual dysfunction, paradoxical excitement.
Endocrinology Advisor Articles
- Clinicians May Be Overtreating Older Patients With Diabetes
- Obesity Risk in Infants Born to Women With Diabetes
- Increased Risk for Mortality in People With Diabetes, CHD Taking Beta-Blockers
- Prediabetes a Useful Indicator for Cardiovascular and Renal Risks
- Autism Does Not Affect Metabolic Control in Type 1 Diabetes
- Gut Microbiota Profiles in Prediabetes
- Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B
- Young Adults With Type 1 Diabetes Show Muscle Metabolic Deficiencies
- Social Support of Autonomy Tied to Better Glycemic Control in Diabetes
- Diabetes May Decrease Ability to Feel Acid Regurgitation